

Press Release

Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes

Heidelberg, Germany, July 19, 2016 – Apogenix, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, today announced that the European Patent Office has granted the Company a patent for the use of CD95 ligand inhibitors including APG101 in the treatment of myelodysplastic syndromes (MDS). The patent covers the use of such inhibitors in low to intermediate-1 risk transfusion-dependent MDS patients and is valid until July 2033.

While Apogenix already holds a broad patent portfolio covering APG101, including composition of matter as well as manufacturing and method of treatment of glioblastoma, this is the first patent to cover its clinical use specifically in MDS patients.

“The granting of this additional patent for APG101 further validates our innovative drug development approach and strengthens the protection of our most advanced asset,” said Thomas Hoeger, Ph.D., CEO of Apogenix. “With the recently announced positive results from the Phase I trial in MDS patients, we now intend to further develop APG101 in this indication, for which today there are no sufficient treatment options available.”

The recently completed Phase I trial evaluated APG101 in low to intermediate-1 risk transfusion-dependent MDS patients and demonstrated the tolerability as well as activity of the drug candidate: APG101 treatment stimulated erythropoiesis and led to a significant decrease in transfusion frequency in this patient population.

To further evaluate the efficacy and safety of APG101 in the treatment of MDS patients, Apogenix is currently in preparation of Phase II proof-of-concept trials.

About Myelodysplastic Syndromes (MDS)

MDS is a bone marrow disorder that is characterized by ineffective hematopoiesis and can lead to severe anemia. In most cases, the anemia is treated with blood transfusions that eventually result in an iron overload, which can damage the liver and other organs. At the same time, the number of thrombocytes that are responsible for coagulation and the number of leucocytes that are responsible for immune defense significantly decrease in patients with this disorder. As a result, MDS patients frequently suffer from sudden bleeding and life-threatening infections. In addition, they are at risk of developing acute myeloid leukemia, a type of blood cancer.

About APG101

Apogenix's lead immuno-oncology candidate APG101 is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG antibody. APG101 is being developed for the treatment of solid tumors and malignant hematological diseases. By blocking the CD95 ligand, which negatively regulates erythrocyte production in MDS patients, APG101 directly addresses the cause of the disorder and could thus potentially provide a cure for MDS.

About Apogenix

Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

Contact

Thomas Hoeger, Ph.D., CEO
Apogenix AG
Phone: +49 (6221) 58 60 80
E-Mail: contact@apogenix.com
Web: www.apogenix.com

Media Contacts

USA:
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1 (212) 845 4272
matt.middleman@russopartnersllc.com

Europe:
Raimund Gabriel
MC Services AG
Phone: +49 (89) 210 228 30
raimund.gabriel@mc-services.eu